Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Cash: 2017-2024

Historic Change in Cash for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to $75.6 million.

  • Kiniksa Pharmaceuticals International's Change in Cash fell 806.54% to -$17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.5 million, marking a year-over-year increase of 478.85%. This contributed to the annual value of $75.6 million for FY2024, which is 612.34% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Change in Cash stood at $75.6 million for FY2024, which was up 612.34% from -$14.8 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's Change in Cash's 5-year high stood at $75.6 million during FY2024, with a 5-year trough of -$14.8 million in FY2023.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Change in Cash had a median value of $245,000 in 2022 and averaged $20.4 million.
  • Its Change in Cash has fluctuated over the past 5 years, first slumped by 6,124.90% in 2023, then soared by 612.34% in 2024.
  • Yearly analysis of 5 years shows Kiniksa Pharmaceuticals International's Change in Cash stood at $67.1 million in 2020, then slumped by 87.75% to $8.2 million in 2021, then crashed by 97.02% to $245,000 in 2022, then crashed by 6,124.90% to -$14.8 million in 2023, then skyrocketed by 612.34% to $75.6 million in 2024.